Literature DB >> 31006875

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.

Frédérique St-Pierre1, Stephen M Broski2, Betsy R LaPlant3, Kay Ristow4, Matthew J Maurer3, William R Macon5, Thomas M Habermann4, Stephen M Ansell4, Carrie A Thompson4, Ivana N M Micallef4, Grzegorz S Nowakowski4, Thomas E Witzig4.   

Abstract

Predicting early clinical failure in patients with untreated follicular lymphoma (FL) is important but difficult. This study aimed to determine the incidence and patterns of extranodal (EN) and spleen disease using PET/CT, and assess their utility in predicting early clinical failure. PET/CT images from 613 cases of untreated FL (2003-2016) were reviewed. The location and number of EN sites, patterns of bone involvement, and splenic involvement were recorded. Outcomes were assessed using event-free survival (EFS), overall survival (OS), and early clinical failure at 24 months (EFS24). So, 49% (301/613) of patients had PET/CT-detected EN involvement, and 28% (171/613) had spleen involvement. The presence of ≥2 EN sites, spleen, bone or soft tissue involvement all predicted failure to achieve EFS24. Presence of ≥2 EN sites and bone involvement pattern were also predictive of OS in a univariate analysis. In a multivariate analysis with FLIPI-2 factors, spleen involvement, pattern of bone involvement, and soft tissue involvement independently predicted a lower EFS (HR 1.49 (1.11-2.00), P = .007; HR 1.71 (1.10-2.65), P = .017; and HR 1.67 (1.06-2.62), P = .026, respectively). When the multivariate analysis was performed using PRIMA-PI factors (marrow and B2M), the number of EN sites was an independent prognostic factor for inferior OS (HR 2.28; P = .05). Baseline PET/CT identifies EN involvement in nearly half of patients with untreated FL. The presence of ≥2 EN sites, bone, soft tissue, or splenic involvement predicts early clinical failure. These results, when combined with other factors, may better identify high-risk patients and guide therapy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Year:  2019        PMID: 31006875     DOI: 10.1002/ajh.25493

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.

Authors:  Frédérique St-Pierre; Stephen M Broski; Betsy R LaPlant; Matthew J Maurer; Kay Ristow; Gita Thanarajasingam; William R Macon; Thomas M Habermann; Thomas E Witzig
Journal:  Oncologist       Date:  2020-04-28

2.  The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.

Authors:  Shintaro Yamanaka; Masao Miyagawa; Yoshifumi Sugawara; Shinji Hasebe; Tomomi Fujii; Kazuto Takeuchi; Keiko Tanaka; Yoshihiro Yakushijin
Journal:  Int J Clin Oncol       Date:  2020-10-23       Impact factor: 3.402

3.  Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma.

Authors:  Alessia Castellino; Aung M Tun; Yucai Wang; Thomas M Habermann; Rebecca L King; Kay M Ristow; James R Cerhan; David J Inwards; Jonas Paludo; Stephen M Ansell; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Blood Cancer J       Date:  2021-01-07       Impact factor: 11.037

4.  Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments.

Authors:  S Jemaa; J N Paulson; M Hutchings; L Kostakoglu; J Trotman; S Tracy; A de Crespigny; R A D Carano; T C El-Galaly; T G Nielsen; T Bengtsson
Journal:  Cancer Imaging       Date:  2022-08-12       Impact factor: 5.605

5.  Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma.

Authors:  Sanjal Desai; Muhamad Alhaj Moustafa; Gregory Wiseman; Thomas Witzig
Journal:  Oncologist       Date:  2021-07-21

6.  The value of 18F-FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation.

Authors:  Zixuan Zhao; Yeye Zhou; Jing Wang; Tongtong Zhang; Jihui Li; Bin Zhang; Qingru Li; Shengming Deng
Journal:  Oncol Lett       Date:  2020-08-31       Impact factor: 2.967

7.  Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks.

Authors:  Skander Jemaa; Jill Fredrickson; Richard A D Carano; Tina Nielsen; Alex de Crespigny; Thomas Bengtsson
Journal:  J Digit Imaging       Date:  2020-08       Impact factor: 4.056

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.